NIT Enterprises, Inc. (DBA Nucleotide Industrial Technologies) (“NIT”) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products; products that enhance the longevity of living and non-living substances based upon unique proprietary nucleotide, (or “NA” for nucleic acid technologies) developed by our award winning scientist and technology team. This new technology is the infusion of nucleotides into a multiplicity of common products enhanced by their presence. The nucleotides were derived by atomic level research that demonstrates their ability to provide screening of ultraviolet (UV) rays at the molecular level.
The Company is authorized to issue an aggregate of 105,000,000 shares of capital stock including 100,000,000 shares of common stock.
As with all business venture, the development of new and innovative products has significant risks and uncertainties, even with advanced patented, patent-pending and proprietary technologies and methods, such as NIT. Some of these risks are discussed next, and Management believes these risks are some of the most significant concerns. Nevertheless, this list is not exhaustive and other issues need traditional discussion and reviews.
There is a risk that NIT’s products could fail to meet regulatory requirements. Despite the advanced techniques and previous significant success of similar products, various complications could cause a selected product to fail certain regulatory requirements. If the selected product failed, additional monies would be needed to test other products. Such other products could also fail regulatory requirements.
There is a risk that NIT’s products, even after completing an initial scientific study, could be difficult to sell, or might not be purchased in volumes sufficient to achieve profitability. NIT’s proposed products have not been commercialized, and no prototypes built. Market risks for new industrial and military applications have increased over the past decade. Tight capital markets and reduced R&D budgets have forced companies to pursue lower risk and later stage licensing methods. Companies typically wait until the product has been shown to be marketable before pursuing an acquisition. Moreover, the proposed markets are difficult to penetrate and characterized by long sales cycles. On the upside, new OTC candidates at this stage can reach values far in excess of anticipated or protection results.
NIT is a development-stage company and subject to all of the risks such companies face. Its financial statements required to be filed with the SEC will be qualified on a going concern basis. NIT has minimal working capital and is dependent upon raising most of the capital it is presently seeking as well as up to $500,000 it anticipates it will need over the 12 months following the offering.
NIT faces technical and market risks. Risks of either kind could cause any investment in the company to be a material, and potentially complete loss.